Out-of-the-Box Solutions for Building Clinical Capacity in Community Settings to Improve Standardized ERBB2 (HER2) Testing in NSCLC
Strategies for Improving ERBB2 (HER2) Testing in NSCLC Within Community Settings
Interactive Practice Guide
The pace at which targetable tumor-specific molecular alterations have been identified over the past decade have ushered in an era of precision oncology, yielding significant insights into the diversity of cancer, offering diagnostic and prognostic benefits, and guiding therapy selection. Indeed, guidelines emphasize that comprehensive biomarker testing should be conducted to identify actionable mutations in non-small-cell lung cancer (NSCLC), including ALK, EGFR, KRAS, MET, RET, and ERBB2 (HER2). These tests guide the selection of targeted therapies that can inhibit oncogenic pathways directly implicated in tumor growth and progression. However, comprehensive molecular testing continues to be underused, especially in community hospital settings. Underlying reasons are many and varied, and include lack of clinical knowledge, lack of multidisciplinary support in the interpretation of test results, shortcomings in tissue samples, lack of access to tests, reimbursement challenges, and turnaround times.
Faculty: Christine Bestvina, MD; Melissa Tjota, MD, PhD
Release Date:
Expiration Date: April 01, 2027
Toolkit: Out-of-the-Box Solutions for Building Clinical Capacity in Community Settings to Improve Standardized ERBB2 (HER2) Testing in NSCLC
Digital Quality ImprovementFaculty: Christine Bestvina, MD; Melissa Tjota, MD, PhD
Release Date:
Expiration Date: April 01, 2028
